CD8A and neoplasm: In BLCA mice models, the combination of oxaliplatin and anti-PD-1 inhibitor could restrict tumor growth and enhance the infiltration of immune cell populations in TIME, including CD3+ T cells, CD4+ T cells, CD8+ T cells, DC cells, and NK cells.